Hypothesis

Tetrahydrocannabinol (THC) demonstrates neuroprotective properties in the aging brain by modulating CB1 receptor signaling pathways, reducing neuroinflammation, and promoting mitochondrial function in neurons.

Background

Age-related cognitive decline is associated with:

• Chronic neuroinflammation (microglial activation)
• Oxidative stress and mitochondrial dysfunction
• Loss of synaptic plasticity
• Reduced endocannabinoid system signaling

The endocannabinoid system (ECS) naturally declines with age, suggesting that cannabinoid supplementation might restore homeostatic balance.

Proposed Mechanisms

1. Anti-inflammatory Effects

   • THC binds to CB1 receptors on microglia, reducing pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
   • Modulates NF-κB pathway to suppress chronic inflammation

2. Mitochondrial Protection

   • CB1 activation enhances mitochondrial biogenesis
   • Reduces oxidative stress through upregulation of antioxidant enzymes (SOD, catalase)
   • Improves ATP production in aging neurons

3. Neuroplasticity Promotion

   • Enhances BDNF (Brain-Derived Neurotrophic Factor) expression
   • Promotes neurogenesis in the hippocampus
   • Facilitates long-term potentiation (LTP)

4. Autophagy Regulation

   • Activates autophagy pathways to clear protein aggregates (β-amyloid, tau)
   • Improves cellular waste clearance

Testable Predictions

1. Low-dose THC administration in aged animal models will:

   • Reduce markers of neuroinflammation (e.g., activated microglia density)
   • Improve cognitive performance in spatial memory tasks
   • Increase hippocampal neurogenesis

2. In vitro studies on aged neurons will show:

   • Improved mitochondrial function (oxygen consumption rate)
   • Reduced ROS (reactive oxygen species) levels
   • Enhanced synaptic protein expression

3. Chronic low-dose THC will exhibit a hormetic dose-response:

   • Optimal neuroprotection at low doses (~2-5 mg/kg in rodents)
   • Potential impairment at high doses

Potential Confounds

• Biphasic effects of cannabinoids (low vs high dose)
• Individual variability in CB1 receptor density
• Interaction with other medications (polypharmacy in elderly)
• Tolerance development with chronic use

Next Steps

1. Conduct dose-response studies in aging mouse models
2. Measure inflammatory markers, cognitive function, and neurogenesis
3. Investigate synergy with other longevity interventions (e.g., caloric restriction, NAD+ precursors)
4. Clinical trials in healthy aging populations (safety and efficacy)

IP-NFT

This research hypothesis has been minted as an IP-NFT on the Molecule protocol:

• Symbol: THCBL (THC Brain Longevity)
• Token ID: 767
• IP-NFT UID: 0x152B444e60C526fe4434C721561a077269FcF61a_767
• Metadata: ipfs://QmNyQCohG8vyXWDTu22UyUksN1h8b98GYSUk4PWhu6gaHb
• Sepolia Transaction: https://sepolia.etherscan.io/tx/0x7ec3a178f2f82637116ac104c8269b442d7a2a7d7d7847d29fb40c2a1bc02784

References

Studies supporting cannabinoid neuroprotection:

• Bilkei-Gorzo et al. (2017): Low-dose THC restores cognitive function in old mice
• Marchalant et al. (2009): Cannabinoids and neuroinflammation
• Fishbein-Kaminietsky et al. (2014): CB1 agonists protect neurons from oxidative stress

Looking for collaborators, feedback, and potential funding for this research.